Skip to main content

Potential Side Costs and Side Benefits of Pharmacological Treatment of Obesity

  • Chapter
  • 154 Accesses

Part of the book series: NATO ASI Series ((NSSA,volume 278))

Abstract

This paper deals with other effects of obesity drugs than weight loss itself and weight loss related effects. The review does not pretend completeness. Rather will the effects — good and bad — be dealt with from examples putting the stress on experience from human studies of clinical relevance.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Andersen, P. H., Richelsen, B., Bak, J.,Schmitz,O.,Sorensen, N. S., Lavielle, R., & Pedersen, O. (1993). Influence ofshort-term dexfenfluramine therapy on glucose and lipid metabolism in obesenon-diabeticpatients.Acta Endocrinologica, 128, 251–258.

    CAS  Google Scholar 

  • Andersen, T., Astrup, A., & Quaade,F. (1989). d-Fenfluramine reduces overweight but does not change food preferences. InternationalJournal of Obesity 13 (suppl 1) A136.

    Google Scholar 

  • Andersson, B., Zimmermann. M. E., Hedner, T.,& Bjorntorp, P. (1991). Haemodymanic, metabolic and endocrine effectsof short-term dexfenfluramine treatment in young, obese women. EuropeanJournal of ClinicalPharmacology40, 249–254.

    CAS  Google Scholar 

  • Astrup, A., Breum, L., Toubro, S., Hein, P., &Quaade,F. (1992), The effect and safety of an ephedrine/caffeinecoumpund compared to ephedrine, caffeine and placebo in obese subjects on anenergyrestricteddiet: A double blind trial. International Journal of Obesity. 16,269–277.

    CAS  Google Scholar 

  • Astrup, A. Buemann, B., Christensen, N.J., Toubro, S., Thorbek, G., Victor, O. J., & Quaade, F. (1992). The effect of ephedrine/caffeine mixture on energy expenditure and bodycomposition in obese women. Metabolism. 41, 686–688.

    Article  CAS  Google Scholar 

  • Atanassoff, P. G., Weiss, B. M., Scmid,E. R., & Tornic, M. (1992). Pulmonary hypertension and dexfenfluramine. Lancet 339 436.

    Article  CAS  Google Scholar 

  • Bartig,K.(1993). Acute and chronic cardiovascular and behavioural effects of caffeine,aspirin and ephedrine.InternationalJournal of Obesity,17(suppl 1). S61–64.

    Google Scholar 

  • Bengtsson, B-A,Eden, S., Lonn. L., Kvist. H., Stokland, A., Lindstedt, G., Bosaeus, I., Tolli,Sjostrom, L., &Isaksson,O. G. P. (1993). Journal of Clinical Endocrinology and Metabolism 76.309–317.

    Article  CAS  Google Scholar 

  • Blundell, J. E. (1992). Serotonin andthe biology of feeding. American Journal of Clinical Nutrition, 55, 155S–159S.

    CAS  Google Scholar 

  • Bradley, M. J., Blum, N. J., &Scheib, R. K. (1974). Mazindol in obesity with known cardiac disease. Journalof InternationalMedical Research,2. 347–354.

    CAS  Google Scholar 

  • Bray, G. A.(1992). Peptides affect the intake of specific nutrients and the sympatheticnervous system.AmericanJournal of Clinical Nutrition 55, 265S–271S.

    CAS  Google Scholar 

  • Drent, M. L., & van der Veen, E. A.(1993) Lipase inhibition: A novel concept in the treatment of obesity. InternationalJournal of Obesity 17 241–244.

    CAS  Google Scholar 

  • Foltin, R. W., Felly, T. H., &Fischman.M. W. (1990). The effect of d-amphetamine on food intake of humans living ina residential laboratory. Appetite 15, 33–46.

    Article  CAS  Google Scholar 

  • Goodall, E.,Feeney, S., McGuirk. J., &Silverstone, T. (1992). A comparison ofthe effects of d- and 1-feniluramineand d-amphetamine on energy and macronutrient intake in human subjects. Psychopharmacologv, 106,221–227

    Article  CAS  Google Scholar 

  • Hitzig. P. (1993).Combined dopamine and serotonin agonists: A synergistic approach to alcoholismandotheraddictive behaviors. Maryland Medical Journal. 42. 153–156.

    CAS  Google Scholar 

  • Kopehnan. P. G.,Elliott, M. W., Smionds. A., Cramer. D , Ward. S.. & Wedzicha. J. A.(1992) Short-termuse of fluoxetine in asymptomatic obese subjects withsleep-related hypoventilation International Journal of Obesity 16, 825–830.

    Google Scholar 

  • Krieger. D. R, Daly, P.A., Dulloo. A. G., Ransil B. J., Young, J. B., & Landsberg, L. (1990).Ephedrine.caffeineandaspum promote weight loss in obese subjects. Transactions of theAssociation of American Physicians 103,307–312.

    CAS  Google Scholar 

  • Marcus. M. D., Wing. R. R., Ewing. L.Kern. E., McDermott. M., & Goodmg. W. (1990) A double-blind, placebo-controlledtrial of fluoxetine plus behavior modification in the treatment of obesebinge-eatersandnon-binge eaters. American Journal of Psychiatry 147, 876–881.

    CAS  Google Scholar 

  • Marin, P., Holmang. S., Jonsson, L., Sjostrom, l., Kvist. H., Hom, G.,Lindstedt. G., & Bjorntorp. P. (1992). The effects of testosterone treatment onbody composition and metabolism in middle-aged men. InternationalJournal of Obesity16, 991–997.

    CAS  Google Scholar 

  • Mathus-Vliegen. E. M. H., van de Voorde. K., Kok, A. M., & Res.A. M. A. (1992). Dexfenfluramine in the treatment of severe obesity: Aplacebo-controlled investigation of the effects on weight loss. cardiovascularrisk factors. food intake and eating behaviour. Journal of InternalMedicine 232 119– 127.

    Article  CAS  Google Scholar 

  • McTavish, D., & Heel. R. C. (1992). Dexfenfluramine. A review of its pharmacological properties and therapeuticpotential in obesity. Drugs 43, 713–733.

    Article  CAS  Google Scholar 

  • Morgan, J. P., & Funderburk. F. K.(1992). Phenylpropanolamine and blood pressure: A review of prospective studies. AmericanJournal of Clinical Nutrition 55, 206S–210S.

    CAS  Google Scholar 

  • Naranjo, C. A., Kadlec, K. E., Sanhueza.P. Woodley-Remus. D., & Sellers. E. M. (1990). Fluoxetrne differentiallyalters alcohol intake and other consummatory behaviors in problem drinkers. Clinical Pharmacology andTherapeutics.47. 490–498.

    Article  CAS  Google Scholar 

  • Pasquali. R., Casimirri. F., Melchionda.N., Grossi, G. Bortoluzzi. L., Labate. A. M. M., Stefanini. C.,& Raitano. A. (1992).Effects of chronic administration of ephedrine during very low calorie diets onenergyexpenditure. protein metabolism and hormone levels inobese subjects, Clinical Science 82, 85–92.

    CAS  Google Scholar 

  • Potter van Loon, B. J., Radder. J. K.,Frolich. M., Krans, H. M. J., Azinderman. A., H., & Meinders, A. E. (1992).Fluoxetrne increases insulin action in obese nondiabetic and in obesenon-insulin-dependentdiabeticindividuals. International Journal of Obesity 16,79–85.

    Google Scholar 

  • Rasmussen, M. H., Frystyk. J., Andersen.T., Breum. L, Christiansen, J. S., & Hilsted, J. (1993). The impact of obesity, fatdistribution and energy restriction on insulin-like growth factor-1 (IGF-1).IGF -bindingprotein-3.insulin and growth hormone. Metabolism, in press.

    Google Scholar 

  • Sax. L (1991). Yohimbine does not affectfat distribution in men. International Journal of Obesity, 15. 561– 565.

    CAS  Google Scholar 

  • Skaggs. S. R. &Crist. D. M.(1991). Exogenous human growth hormone reduces body fat in obese women. Hormone Research, 35, 19–24.

    Article  CAS  Google Scholar 

  • Snyder, D. K., Underwood, L. E., &Clemmons, D. R. (1990). Anabolic effects of growth hormone in obese diet-restrictedsubjects are dose dependent. American Journal of Clinical Nutrition, 52,431–437.

    CAS  Google Scholar 

  • Spring, B., Pingitore, R., & Kessler, K. (1992).Strategies to minimize weight gain after smoking cessation: Psychological andpharmacological intervention with specific reference to dexfenfluramine. InternationalJournal of Obesity, 16(suppl 3) S19–23.

    Google Scholar 

  • Visser. M., Seidell. J. C.,Koppeschaar, H. P. F., & Smits, P. (1993). The effect of fluoxetine onbody weight, body composition and visceralfat accumulation. International Journal of Obesity. 17, 247–253.

    CAS  Google Scholar 

  • Weintraub, M. (1992). Long-term weightcontrol study: Conclusions. Clinical Pharmacology and Therapeutics 51,642–646.

    Article  CAS  Google Scholar 

  • Wurtman,J. J. & Wurtman, R. J. (1984). d-Fenfluramine selectively decreasescarbohydreate but not protein intake in obese subjects. InternationalJournal of Obesity, 8(suppl 1), 79–84.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer Science+Business Media New York

About this chapter

Cite this chapter

Andersen, T. (1995). Potential Side Costs and Side Benefits of Pharmacological Treatment of Obesity. In: Allison, D.B., Pi-Sunyer, F.X. (eds) Obesity Treatment. NATO ASI Series, vol 278. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1901-0_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-1901-0_21

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5776-6

  • Online ISBN: 978-1-4615-1901-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics